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Abstract
Purpose
Lung cancer screening with CT has been recently recommended for decreasing lung can-
cer mortality. The radiation dose of CT, however, must be kept as low as reasonably achiev-
able for reducing potential stochastic risks from ionizing radiation. The purpose of this study
was to calculate individual patients’ lung doses and to estimate cancer risks in low-dose CT
(LDCT) in comparison with a standard dose CT (SDCT) protocol.
Materials and Methods
This study included 47 adult patients (mean age 63.0 ± 5.7 years) undergoing chest CT on
a third-generation dual-source scanner. 23/47 patients (49%) had a non-enhanced chest
SDCT, 24 patients (51%) underwent LDCT at 100 kVp with spectral shaping at a dose
equivalent to a chest x-ray. 3D-dose distributions were obtained from Monte Carlo simula-
tions for each patient, taking into account their body size and individual CT protocol. Based
on the dose distributions, patient-specific lung doses were calculated and relative cancer
risk was estimated according to BEIR VII recommendations.
Results
As compared to SDCT, the LDCT protocol allowed for significant organ dose and cancer
risk reductions (p<0.001). On average, lung dose was reduced from 7.7 mGy to 0.3 mGy
when using LDCT, which was associated with lowering of the cancer risk from 8.6 to 0.35
per 100’000 cases. A strong linear correlation between lung dose and patient effective
diameter was found for both protocols (R2 = 0.72 and R2 = 0.75 for SDCT and LDCT,
respectively).
Conclusion
Use of a LDCT protocol for chest CT with a dose equivalent to a chest x-ray allows for signif-
icant lung dose and cancer risk reduction from ionizing radiation.
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Introduction
During the past decade, several studies focused on low-dose computed tomography (LDCT)-
based screening for lung cancer [1–5]. According to the National Lung Screening Trial
(NLST), lung cancer screening with LDCT has shown a survival benefit with a 20% reduction
in lung cancer related mortality [6, 7]. However, there is an ongoing debate related to the radia-
tion dose of LDCT and its associated potential risk of radiation-induced lung cancer. This is
particularly important for screening programs due to the cumulative dose associated with
repeated CT examinations in large cohorts of individuals.
The majority of the LDCT protocols used in current lung cancer screening trials were
mainly achieved by reducing the tube current down to 40 mAs, resulting in estimated effective
doses of 1–1.5mSv per CT examination [8–10]. Third-generation dual-source CT is equipped
with a selective photon shield that eliminates lower energy photons from the x-ray spectrum,
thus allowing for further radiation dose reduction[11]. Recent studies have shown that the esti-
mated effective dose from chest CT can thus be reduced down to 0.06 mSv, being at the level of
conventional chest x-ray while maintaining a good image quality of the examination [11–15].
In all these studies effective doses were estimated based on volume CT dose index (CTDIvol)
values taken from the electronically logged protocols. Although this approach allows for com-
parison between different CT protocols, the CTDIvol reflects the dose in uniform phantoms
and cannot be used as the patient-specific dose [16, 17]. A more accurate assessment requires
organ dose calculations taking the individual patient body habitus into account. In addition,
the individual organ dose is also a better measure for estimating patient risk, because the effec-
tive dose is intended for estimating the radiation exposure of entire populations and not for
individuals [17–19].
The aim of this study was to calculate individual patient lung doses and lifetime attributable
risk of lung cancer from a LDCT protocol of the chest at a radiation dose equivalent to that of a
chest x-ray and to compare these values with those from a standard chest CT protocol. Since
lung cancer screening was recommended for individuals between the age of 55 and 74 years
[10, 20], we focused our study explicitly on patients in this age group.
Materials and Methods
Patient population
The study included 47 consecutive patients between 55 and 74 years of age (mean age 63.0 ± 5.7
years; 27 males, mean age 64.0 ± 5.8 years and 20 females, mean age 63.0 ± 6.9 years) who were
referred to our department for non-enhanced chest CT. Mean body mass index (BMI) was
26.3±5.6 kg/m2. Indications for chest CT were as follows: diffuse parenchymal lung disease
(n = 23); this group underwent imaging with our standard dose CT (SDCT) protocol, and fol-
low-up of known pulmonary nodules (n = 15) and suspicion of pulmonary infection in immu-
nodeficient patients (n = 9); the latter patients (total n = 24) underwent imaging with our
LDCT protocol described below.
This study had local institutional review board approval (Kantonale Ethikkommission
Zürich) for retrospective use of CT images, from which identifying information has been
removed. Written informed consent was waived because of the retrospective nature of the study.
CT scanning and reconstruction
All patients were scanned cranio-caudally on a third-generation 192-slice dual-source CT scan-
ner (SOMATOM Force, Siemens Healthcare, Forchheim, Germany) operated in the single-
source mode.
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Twenty-four of the 47 patients (51%) were scanned with the SDCT protocol with automatic
attenuation-based tube voltage selection (CAREkV, Siemens) and attenuation-based tube cur-
rent modulation (CareDose4D, Siemens) with quality reference values of 120 kVp and 70 mAs.
The other twenty-three patients (49%) were scanned with LDCT at 100 kVp and with a quality
reference tube current-time product of 45 mAs, as previously shown [11, 13, 15]. A 0.6 mm Sn-
filter was used for spectral shaping by eliminating low energy photons from the spectrum. A
pitch of 1.2, collimation of 0.6×96 mm using the z-flying focal spot, and a gantry rotation time
of 0.5 seconds were used for both protocols. All CT images were reconstructed using a slice
thickness of 2 mm, an increment of 1.6 mm, and using a sharp tissue convolution kernel (Bl64)
with advanced modeled IR (ADMIRE) at a strength level of 3, as previously shown [13].
Image quality analysis
One reader (K.M., with two years of experience in radiology), not involved in qualitative analy-
sis, placed five circular region of interests (ROIs) in the subcutaneous fat tissue of each patient
scanned with both SD and LDCT. The ROI size was fixed at 380 mm2. Average image noise
was defined as the standard deviation of attenuation in consecutive ROIs at different slice posi-
tions, as previously shown elsewhere [13].
For both patient groups, subjective image quality (diagnostic vs. non-diagnostic) was evalu-
ated by two other, independent readers (H.A., with 15 years of experience in radiology, T.F.
with 14 years of experience in radiology).
Monte Carlo simulations
Monte Carlo (MC) simulations were performed by using a commercially available software
tool (ImpactMC, CT Imaging GmbH, Erlangen, Germany) to obtain 3D dose distributions.
The accuracy of the tool was previously validated in anthropomorphic phantoms for both axial
and spiral scanning modes [21]. MC simulations were performed using specific scanner geom-
etry, filtration, collimation and tube voltage as used for the respective CT examinations. Indi-
vidual patient images acquired from CT scanner were used as an input volume for MC
simulations. The original tube current modulation curves together with start and end angular
position of the tube were extracted from the raw data using a manufacturer-provided tool.
Organ dose calculation
Based on a 3D dose distribution, any organ dose within the volume can be calculated as a mean
value of all voxels assigned to a given organ. The voxels associated with lung tissue were identi-
fied based on the CT data explicitly for each patient by using global HU-based thresholding
(ImageJ software). Then the lungs dose was calculated from the 3D dose distribution as a mean
dose value within the segmented volume.
In order to investigate the organ dose dependency on patient size, we measured the individ-
ual patients’ lateral diameter Dlat and the antero-posterio diameter Dap using their CT images.
The effective diameter Deff was calculated as follows:
Deff ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Dlat  Dap
q
ð1Þ
and was used as an indicator of patient size.
Risk assessment
To estimate the potential risk of radiation-induced lung cancer we used a model proposed by
BEIR VII [22]. This model was designed for estimating the lifetime attributable risk of an
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exposed individual developing cancer. According to BEIR VII the risk can be calculated as fol-
lows:
Rn ¼
Dn
0:1
 ka;gn ð2Þ
Rn is the number of cancer cases per 100’000 persons for a speciﬁc organ n; Dn is the organ
dose in Gy, and kn
a,g is an age- and gender-speciﬁc risk coefﬁcient for organ n. The coefﬁcients
kn
a,g are tabulated in the BEIR VII report for males and females at discrete ages of 0, 5, 10, 15,
20, 30, 40, 50, 60, 70 and 80 years. Values of the risk coefﬁcient at intermediate ages were deter-
mined by using linear interpolation. Since the individual risk depends not only on the organ
dose but also on patient age and gender (see Eq 2), patients were divided into 3 age groups (55–
60 years, 61–67 years, and 68–74 years). The average risk values within each age group were
calculated separately for male and female patients in both LDCT and SDCT cohorts.
Data analysis
All statistical analyses were performed using commercially available software (SPSS, release
22.0; SPSS, Chicago, IL, USA). Normal distribution was tested using the Shapiro-Wilk test.
Post-hoc power analysis showed that a sample size of 24 in each patient group will provide a
significant Pearson correlation with a medium effect size at a 0.05 level of significance and a
power of 80%. Linear regression analysis was performed to assess the correlation between lung
dose and patient effective diameter for both SDCT and LDCT protocols. The Student t-test for
independent samples was performed to determine the significance of the differences in lung
doses in LDCT and SDCT chest protocols. The same t-test was applied to show the significant
difference in risk values estimated for LDCT protocol compared to SDCT one. A two-tailed p-
value below 0.05 was considered to indicate a statistically significant difference.
Results
Representative image examples of two patients scanned with SDCT and with LDCT are pro-
vided in Fig 1. The lung dose for the patient scanned with the SDCT protocol equaled 5.6 mGy,
while the lung dose for the patient scanned with LDCT was 0.44 mGy. Both CT examinations
were considered to be of diagnostic image quality.
Fig 2 shows an example of patient CT data and respective 3D dose distribution within the
patient volume obtained by MC simulations. It can be seen that the spiral trajectory of the x-
ray tube with a pitch of 1.2 is reflected by spiral stripes in dose distribution.
Organ dose
Tables 1 and 2 show the patient age, gender, effective diameter, and the lung dose calculated
fromMC simulations for SDCT and LDCT, respectively. Both SDCT and LDCT patient popu-
lations categorized by age and effective diameter were normally distributed. The average lung
dose was 7.7 mGy (range 4.9–10 mGy) and 0.3 mGy (range 0.16–0.52 mGy) for SDCT and
LDCT, respectively.
The results for lung dose as a function of patient size (effective diameter) for both protocols
are shown in Fig 3. With the SDCT protocol the absolute dose values to the lungs were an order
of magnitude higher than those from the LDCT protocol (p<0.001). Regression analysis showed
a strong linear correlation between patient size and lung dose for both protocols (R2 = 0.72 and
R2 = 0.75 for SDCT and LDCT, respectively).
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Fig 1. Representative transverse CT sections of a female patient with a nodule (arrow) scanned with a standard dose protocol
(lung dose 5.6 mGy) (a), and a male patient with a ground glass nodule at the fissure (arrow) scanned with a low-dose CT protocol
(lung dose 0.44 mGy) (b).
doi:10.1371/journal.pone.0155722.g001
Fig 2. Coronal reformation of the CT for female patient (a) and corresponding dose distribution obtained by Monte Carlo
simulations (b). Note the spiral trajectory of the x-ray tube leading to heterogeneous dose distributions.
doi:10.1371/journal.pone.0155722.g002
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Lung cancer risk
The average lifetime attributable risk of lung cancer from a single CT examination calculated
for male and female patients in separate age groups is shown in Fig 4. The estimated cancer
risk values for females were significantly higher than those for males in both LDCT and SDCT
protocols (p = 0.004, p = 0.001) (Table 1). The estimated lifetime attributable risk of lung can-
cer was significantly lower for the LDCT as compared to the SDCT protocol (p<0.001). The
risk dropped with higher patient age for both protocols.
Discussion
In this study we calculated patient-specific lung doses and estimated lifetime attributable can-
cer risks from chest CT. We compared two different protocols, a SDCT and a recently intro-
duced LDCT protocol with a radiation dose being equivalent of that from chest x-ray, which is
reported to be in the range of 0.02mSv for posteroanterior studies and in the range of 0.1mSv
for anteroposterior and lateral chest studies [23]. Unlike previous researchers [12–14], we per-
formed dose assessments based on Monte Carlo simulations, taking examination- and patient-
specific parameters into account. In a comparison with the rough estimations based on
Table 1. Dose and relative cancer risk for each individual patient (male-M, female-F) calculated for the standard dose protocol, sorted by patient
age.
Standard dose protocol
Patient gender Patient age, [years] Patient effective diameter, [cm] Lung dose, [mGy] Risk, [cases/ 105]
F 55 27.20 8.20 17.67
M 55 30.85 9.00 8.55
F 56 22.65 4.89 10.40
M 58 32.03 9.20 8.30
M 59 31.75 8.20 7.49
M 60 32.65 8.60 7.65
M 62 24.49 6.50 5.47
F 63 30.50 9.30 17.19
F 63 26.27 6.65 12.29
M 64 27.48 8.77 6.96
M 64 23.24 5.33 4.23
M 64 31.19 7.90 6.27
F 65 25.10 5.60 9.74
M 65 28.55 9.30 7.16
F 67 27.71 7.20 11.75
M 68 24.68 5.70 3.98
M 68 30.82 8.40 5.86
F 69 25.69 7.74 11.80
F 69 27.53 8.30 12.65
M 71 34.00 9.04 5.60
M 72 36.00 10.00 5.88
M 74 29.91 7.82 4.11
F 76 25.92 6.70 7.97
Mean 64.65 28.53 7.75 8.65
Maximum 76.00 36.00 10.00 17.67
Minimum 55.00 22.65 4.89 3.98
doi:10.1371/journal.pone.0155722.t001
Organ Dose and Cancer Risk in Lung Cancer CT Screening
PLOS ONE | DOI:10.1371/journal.pone.0155722 May 20, 2016 6 / 11
CTDIvol values automatically generated by the scanner, this approach allows not only to esti-
mate the effective dose, but also to calculate the individual patients’ dose to the lungs, and thus,
to estimate individual lifetime attributable risks of lung cancer.
This work explicitly focused on lung dose due to the following reason. In contrast to the
radiation-associated lifetime attributable cancer risk for most of other organs, which are high-
est at younger ages, the excess risk for radiation-induced lung cancer is highest in those aged
approximately 55 years at exposure [22, 24]. Our study has shown that the dose to the lungs
can be significantly reduced when using a LDCT instead of a standard dose protocol. In addi-
tion, we could demonstrate a strong linear dependency between lung dose and effective patient
diameter for both protocols. This can be explained by the fact that although the CT scanner
adjusts the mAs values to the patient size according to an exponential function, the additional
adipose tissue in more obese patients serves as natural shielding and thus, the dose for inner
organs increases more slowly and can be approximated with a linear function. Similar organ
dose dependency on patient size has been already shown by other researchers [25].
The risk assessment performed in the study showed that for both males and females the life-
time attributable cancer risk is decreasing with patient age for both LDCT and SDCT protocols.
This can be explained by the fact that risk is not only a function of organ dose but also strongly
Table 2. Dose and relative cancer risk for each individual patient (male-M, female-F) calculated for the low dose protocol, sorted by patient age.
Ultra-low dose protocol
Patient gender Patient age, [years] Patient effective diameter, [cm] Lung dose, [mGy] Risk, [cases/ 105]
F 55 28.91 0.299 0.64
F 55 24.6 0.23 0.50
M 56 34.07 0.45 0.42
M 56 32.86 0.4136 0.39
F 57 23.8 0.17 0.36
M 58 30.20 0.44 0.40
M 59 30.8 0.35 0.32
M 59 30.6 0.26 0.23
M 60 30.0 0.43 0.38
F 61 26.27 0.2 0.39
F 61 24.90 0.18 0.35
M 61 25.0 0.16 0.14
F 64 35.0 0.52 0.93
M 65 32.0 0.32 0.25
F 65 26.0 0.16 0.28
F 66 23.66 0.19 0.32
M 66 30.0 0.32 0.24
F 68 29.1 0.24 0.38
M 69 26.12 0.16 0.11
F 69 29.56 0.28 0.43
M 69 31.1 0.34 0.23
F 72 32.4 0.51 0.68
M 73 30.0 0.25 0.14
M 74 28.98 0.26 0.14
Mean 63.61 29.00 0.30 0.35
Maximum 74.00 35.00 0.52 0.93
Minimum 55.00 23.66 0.16 0.11
doi:10.1371/journal.pone.0155722.t002
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depends on patient age [22]. Therefore, even if the radiation dose to the lungs for some individ-
uals was higher due to the greater body size, the average risk in older patients (group above 60
years of age) was lower.
Although we found that the lifetime attributable risk for lung cancer from a single LDCT
examination was comparatively low, screening would yield higher risk values due to the need
for repeated CT examinations. For example, the NLST trial participants received screening
with annual low-dose CT for 3 years [26]. In the largest European NELSON trial, current
smokers or former smokers who had quit smoking less than 10 years ago underwent one CT
Fig 3. Scatter plots showing the correlation between lung dose and patient effective diameters for standard dose (SDCT) and low-
dose CT (LDCT) examinations.
doi:10.1371/journal.pone.0155722.g003
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examination in years 1, 2, 4 and 6 [27]. The most recent guidelines of American Cancer Society
and National Comprehensive Cancer Network recommended LDCT screening for individuals
above 55 in each year until the age of 74 [28]. Therefore, the number of CT examination proce-
dures in cancer screening programs varied with the factor 3 up to 25. Given the average lung
dose of 7 mGy and 0.3 mGy and corresponding lifetime cancer risk of 8.6 and 0.35 cases per
100’000 population from a single SDCT and LDCT, respectively, as calculated in this study,
lung cancer screening as recommended by these societies will be associated with an increase of
the attributable lifetime cancer risk up to 215 and 8.7 cases per 100’000 population for SDCT
and LDCT, respectively. Thus, it is especially important to keep the radiation dose values from
individual CT examinations as low as reasonably achievable (the so-called ALARA principle in
radiologic imaging with ionizing radiation). By confirming previous studies, we could show
that a LDCT protocol applying various radiation dose saving techniques allows for CT lung
imaging at a dose equivalent to that of a chest x-ray (0.06mSv).
Fig 4. Estimated lifetime attributable risk of cancer as a function of age for males and females from single standard dose (SDCT)
and low-dose CT (LDCT) examination.
doi:10.1371/journal.pone.0155722.g004
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The following study limitations must be acknowledged. First, the patient CT data used as an
input volume for MC simulations was limited by the length of the scan and thus, does not
include over-scanning effects in the calculations. However, since in all CT examinations the
lung volume was completely covered by the scan range, the effect of over-scanning on the lung
dose can be considered negligible [29]. Second, the accuracy of our risk estimations is limited
by the uncertainties of current cancer risk models, based on the life-span studies of atomic
bomb survivors. Furthermore, the risk coefficients published in the BEIRVII report and used
in this study are statistical averages over many individuals of the same gender and similar age.
Therefore, care must be taken when interpreting the results of individual patient risk. Never-
theless, the patient-specific risk information as presented in our study represents a step forward
beyond effective dose towards personalized patient care Finally, we only investigated one CT
scanner from one manufacturer. Since the selective photon shield for single energy is currently
a unique technique from one vendor only, results of this study cannot be extrapolated to other
systems.
In conclusion, our study determined patient- and examination-specific lung dose values,
allowing for individual patient risk assessments, which is mandatory when balancing the bene-
fits and risks from ionizing radiation in the context of lung cancer screening with CT. The lung
doses calculated in this study further enhance the need for employing LDCT protocols to lung
screening studies for keeping the risk to the general population as low as reasonably possible.
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